Trial Profile

EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms EVO-HF; EVO-HF pilot

Most Recent Events

15 Jun 2023 Results assessing the effects of Evolocumab on heart failure with reduced ejection fraction (HFrEF) injury biomarkers, published in the European Journal of Heart Failure.
10 Aug 2022 Status changed from active, no longer recruiting to completed.
19 Nov 2021 Planned number of patients changed from 56 to 46.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com